PharmaLundensis (PHAL) Q4 2024 earnings summary

Executive summary

• No revenue generated in 2024; net loss after financial items improved to -3.85 MSEK from -4.40 MSEK year-over-year.

• Synthesis of Phal-501 completed, positive patent review received, and successful animal toxicity tests conducted.

• Active discussions ongoing for sale or licensing of Minievaporator project; potential for significant revenue in 2025.

• February 2025 rights issue aims to raise up to 14.4 MSEK to fund clinical studies and operations.

Financial highlights

• Net sales remained at 0 SEK for both Q4 and full year 2024, unchanged from prior year.

• Net loss after financial items for Q4 improved to -1.20 MSEK from -1.53 MSEK; full year net loss improved to -3.85 MSEK from -4.40 MSEK year-over-year.

• Earnings per share for 2024 improved to -0.08 SEK from -0.10 SEK year-over-year.

• Equity ratio at year-end was 33%.

• Cash and bank balances at year-end totaled 1.27 MSEK, down from 2.50 MSEK prior year.

Outlook and guidance

• First clinical study with Phal-501 for chronic bronchitis planned, pending successful capital raise.

• Minievaporator project expected to generate significant revenue, possibly as early as spring 2025 if sold to a large company.

• February 2025 rights issue proceeds will accelerate clinical trial initiation.